The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines through pay-for-delay agreements (Lundbeck)

Brief, European Competition Network

Previous article The US FTC submits brief amicus curiae in a pay-for-delay case in which it supports the absence of a cash payment is not determinative in the pharmaceutical sector (In Re Effexor XR) Next article The EU Commission imposes fines totaling up to €145 million on a Danish pharmaceutical group over pay-for-delay agreements (Lundbeck)

19 Jun 2013

The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines through pay-for-delay agreements (Lundbeck)

KEYWORDS

Reference

EU Commission, Lundbeck, Press Release, 19 June 2013

European Commission: Lundbeck and other Pharmaceutical Companies fined for delaying Market Entry of Generic Medicines through pay-for-delay Agreements* On 19 June 2013, the European Commission (the Commission) imposed a fine on the Danish pharmaceutical company Lundbeck and a number of generic companies (notably Merck KGaA/Generics UK (Generics UK is now part of Mylan), Arrow (now part of Actavis), Alpharma (now part of Zoetis), and Ranbaxy) for delaying the market entry of generic citalopram medicines through pay-for-delay agreements. The Commission

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

European Competition Network Brief
European Commission

Belgium 714 contributions 215392 visits

Quotation

European Competition Network Brief, The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines through pay-for-delay agreements (Lundbeck), 19 June 2013, e-Competitions Pay-for-delay agreements, Art. N° 53279

Visites 737